About
LTZ Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies that empower myeloid cells to enhance anti-tumor immunity. Their Universal Myeloid Cell Engager (U-MCETM) platform aims to address unmet clinical needs in oncology and autoimmune diseases by directly engaging myeloid cells to activate killing mechanisms and reprogram the tumor microenvironment.
Tags
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does LTZ Therapeutics do?
LTZ Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies that empower myeloid cells to enhance anti-tumor immunity. Their Universal Myeloid Cell Engager (U-MCETM) platform aims to address unmet clinical needs in oncology and autoimmune diseases by directly engaging myeloid cells to activate killing mechanisms and reprogram the tumor microenvironment.
How much funding has LTZ Therapeutics raised?
LTZ Therapeutics has raised a total of $76M in funding. The most recent round on record is Series B.
Where is LTZ Therapeutics headquartered?
LTZ Therapeutics is headquartered in Redwood City, California, USA.
When was LTZ Therapeutics founded?
LTZ Therapeutics was founded in 2021.
What industry does LTZ Therapeutics operate in?
LTZ Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech, Biotech, Drug Discovery, Clinical Trials.
Similar Startups